

AWARD NUMBER: W81XWH-19-1-0716

TITLE: Development of Molecular Chaperone Inhibitors for (Re)Sensitization of CRPC to Enzalutamide and Abiraterone and to Synergize with Metabolic Inhibitors

PRINCIPAL INVESTIGATOR: Dr. Leonard Neckers

CONTRACTING ORGANIZATION: Geneva Foundation, Tacoma, WA

REPORT DATE: October 2023

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution is unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

*Form
Approved
OMB No.
0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2023		2. REPORT TYPE Annual		3. DATES COVERED 15Sep2022 – 14Sep2023	
4. TITLE AND SUBTITLE Development of Molecular Chaperone Inhibitors for (Re)Sensitization of CRPC to Enzalutamide and Abiraterone and to Synergize with Metabolic Inhibitors				5a. CONTRACT NUMBER W81XWH-19-1-0716	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Leonard Neckers E-Mail: neckersl@mail.nih.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Geneva Foundation 950 Broadway Suite 307 Tacoma WA 98402 National Cancer Institute				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) USAMRMC	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Objective: (1) Improve the solubility and pharmacodynamic properties of previously identified Hsp40 & Hsp70 inhibitors in preparation for Phase I clinical evaluation in CRPC patients. (2) Determine whether these chaperone inhibitors sensitize resistant CRPC to Enz and/or Abi and, if so, by what mechanism(s). (3) Increase our understanding of the role of these chaperones in regulating CRPC metabolic deregulation, with the goal of identifying novel synergistic combinatorial approaches to target CRPC. Impact: By identifying a chaperone-based approach to inhibit or reverse CRPC resistance to Enz and/or Abi, the current research proposal addresses the dual 2018 PCRP Overarching Challenges of (1) developing treatments that improve the outcomes for men with lethal prostate cancer and (2) better defining the biology of lethal prostate cancer to reduce death. Further, consistent with the mandate of the PCRP Impact Award, a key goal of our research strategy is to position the program for first-in-human clinical evaluation of one or more of these chaperone inhibitors within 5 years after completion of this Award.					
15. SUBJECT TERMS Cancer, prostate cancer, oncology					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified	14	19b. TELEPHONE NUMBER <i>(include area code)</i>

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	10
5. Changes/Problems	11
6. Products	12
7. Participants & Other Collaborating Organizations	13
8. Special Reporting Requirements	14
9. Appendices	14

1. INTRODUCTION: *Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.*

Androgen receptor (AR) signaling remains important in CRPC. Accordingly, two potent second line anti-androgen agents, abiraterone and enzalutamide, were developed. Abiraterone is a CYP17A1 inhibitor (blocking both 17-alpha-hydroxylase and 17,20 desmolase enzymatic activities) which causes a marked reduction of androgen in serum and in CRPC osseous metastases. Enzalutamide is a competitive antagonist of AR, which binds the ligand binding domain (LBD), preventing nuclear translocation and AR-dependent gene transcription. Unfortunately, most patients that initially respond to these drugs develop resistance, concomitant with reactivated AR signaling. The emergence of ADT-resistant CRPC is frequently associated with expression of a number of AR splice variants (ARv), including but not limited to ARv7, which lack a carboxy-terminal LBD. Consequently, these ARv are insensitive to antiandrogens or androgen ablation and are constitutively active. Notably, ARv7 expression has been associated with poor prognosis, shorter overall survival and resistance to standard of care treatments in CRPC patients. In addition to ARv expression, another key mechanism underlying resistance to enzalutamide is metabolic dysregulation through enhanced dependence on glucose metabolism. PCa is characterized by dependence on glycolysis and altered fatty acid and glutamine metabolism, and this metabolic reprogramming is regulated, in part, by the transcriptional activity of full-length AR. Expression of ARv (in particular, ARv7) has been shown to further increase dependence of CRPC on glutaminolysis and reductive carboxylation. Thus, alternative approaches to disrupt the AR and ARv7 signaling axis and its effects on metabolic dysregulation and ADT resistance in CRPC are of great clinical importance and remain a critical unmet need. Such a strategy would be expected to provide efficacy in CRPC and may also (re-)sensitize ADT-resistant CRPC to LBD targeted therapy (e.g., enzalutamide and/or abiraterone). The research plan described in the current proposal builds on the current team's multi-year ongoing and successful collaboration, funded by the 2015 PCRP Idea Development Award, that identified Hsp40 and Hsp70 inhibitors as novel therapeutic agents with in vitro and in vivo activity toward enzalutamide- and abiraterone-resistant CRPC expressing AR splice variants, including ARv7. The current research proposal addresses the dual 2018 PCRP Overarching Challenges of (1) developing treatments that improve the outcomes for men with lethal prostate cancer and (2) defining the biology of lethal prostate cancer to reduce death. Further, consistent with the mandate of the PCRP Impact Award, a key goal of our research strategy is to position the program for first-in-human clinical evaluation of one or more of these chaperone inhibitors within 5 years after completion of this Award.

2. KEYWORDS: *Provide a brief list of keywords (limit to 20 words).*

castration-resistant prostate cancer, androgen, androgen receptor, ARv7, chaperone inhibitors, Hsp70, Hsp40, metabolism, glycolysis, oxidative phosphorylation
--

3. ACCOMPLISHMENTS: *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.

SA1/Major Task 1: Synthesis and characterization of sufficient amounts of C86, JG-98, JG- 231 and other analogs.

Milestones	target dates	actual dates	%completion
n/a	1-36 months	12-36 months	75%

SA1/Major Task 2: Lead optimization of JG-231 analogs. From this Task, we will produce 1-2 optimized candidates for testing in efficacy models.

Milestones	target dates	actual dates	%completion
n/a	1-18 months	12-36 months	75%

SA1/Major Task 3: Hit-to-lead optimization of C86 and analogs. From this Task, we will identify the binding site of C86 and understand whether this site can accommodate drug-like molecules.

Milestones	target dates	actual dates	%completion
n/a	12-36 months	12-36 months	25%

SA2/Major Task 4: Assess combinatorial activity of chaperone inhibitors in 3 resistant CRPC models (22Rv1, VCaP, C4-2).

Milestones	target dates	actual dates	%completion
Validate Hsp40/70 inhibitors re-sensitize resistant CRPC cells and tumors to enzalutamide and/or abiraterone	1-18 months	12-36 months	85%

SA2/Major Task 5: Determine mechanistic basis of combinatorial activity underlying chaperone inhibitor-mediated re-sensitization to enzalutamide and/or abiraterone.

Milestones	target dates	actual dates	%completion
Identify one or more mechanisms by which Hsp40 and/or Hsp70 inhibitors re-sensitize resistant CRPC cells to enzalutamide and/or abiraterone.	6-18 months	12-36 months	80%

SA3/Major Task 6: Assess combinatorial activity of Hsp40 and Hsp70 inhibitors with inhibitors of glycolysis, pentose phosphate pathway, glutaminolysis and fatty acid synthesis.

Milestones	target dates	actual dates	%completion
Identify synergy between chaperone inhibitors and selected metabolic inhibitors; identify metabolic pathways, whose inhibition (alone or combined with chaperone inhibition) re-sensitizes resistant CRPC to enzalutamide and/or abiraterone; validate non-invasive HP-MRSI to predict treatment efficacy <i>in vivo</i> .	12-36 months	12-36 months	70%

Specific Aims:

1. Initiate a pre-clinical development program to improve solubility and pharmacokinetic properties of Hsp40 & Hsp70 inhibitors to maximize *in vivo* safety, efficacy and bioavailability.
2. Examine whether current Hsp40 and/or Hsp70 inhibitors sensitize CRPC to Enz and/or Abi *in vitro* and *in vivo*, and by what mechanism(s).
3. Determine whether additive/synergistic activity is observed in CRPC when Hsp40/Hsp70 inhibition is combined with inhibitors of distinct metabolic pathways deregulated in CRPC.

What was accomplished under these goals?

For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.

Specific Aim 1: The goal of Specific Aim 1 is to advance the development of clinical candidates targeting Hsp70 and Hsp40. In earlier funding cycles, we focused on target validation and compound selectivity. Recent hit-to-lead work produced a set of chemical probes, such as JG-98, JG-194, JG-231 and JG-294, that interrupt Hsp70 function by binding to an allosteric site (Shao et al. 2018 J. Med. Chem.) and we had shown that some of these molecules have promising anti-proliferative activity in cellular and animal models of CRPC (Moses et al. 2018 Cancer Res). Our collaborator, Prof. Gestwicki, has developed a number of additional Hsp70 inhibitors, based on the JG platform, and we will evaluate them both *in vitro* and *in vivo* for efficacy in CRPC models used in this award. Unfortunately, further development of Hsp40 inhibitors based on the C86 platform has been lagging. **To remedy this situation, we added Dr. Yeong Sang Kim, a medicinal chemist, as a part-time contractor to provide his expertise in the design of novel C86 derivatives for synthesis and for *in vitro/in vivo* testing. Dr. Kim has designed 11 novel structures based on C86 and we have engaged the CRO Karebay Biochem, Inc to synthesize them in quantities suitable for *in vitro* testing. We have obtained mg quantities of 8 of 11 compounds designed by Dr. Kim, and these will be evaluated *in vitro* in the coming cycle. Compounds displaying good *in vitro* activity will be scaled up for *in vivo* testing in the coming cycle. Included in this novel set of C86 derivatives are compounds expected to localize to the mitochondria (see rationale below), which is a natural characteristic of JG-98.**

Specific Aim 2: The goal of Specific Aim 2 (and a Major Task under this aim) was to determine whether Hsp40 and/or Hsp70 inhibitors re-sensitize resistant CRPC to enzalutamide and/or abiraterone. In a previous publication (Moses MA, et al. Cancer Res. 2018) we demonstrated that the Hsp40 inhibitor C86 and the Hsp70 inhibitor JG-98 each had single agent activity toward 22Rv1 CRPC cells *in vitro* and *in vivo*. In the last cycle, we confirmed and expanded on these findings using the Incucyte instrument which supports multi-concentration 6-day analysis of cell growth that can be monitored in real time. Unexpectedly, CRPC sensitivity to JG-98 was not impacted by siRNA knockdown of either full-length androgen receptor or Arv7, the constitutively active androgen-independent androgen receptor splice variant (see Fig. 1).





Fig. 1. siRNA targeting either exons 1, 3 or CE3 (see cartoon above and accompanying western blot upper right) does not enhance JG-98 mediated ADT resensitization as measured by Incucyte growth analysis (3 growth curves). ENZ, enzalutamide).

In experiments from the Moses et al. 2018 Cancer Research paper (DOI: 10.1158/0008-5472.CAN-17-3728), we exposed 22Rv1 CRPC cells for 6 hrs to micromolar concentrations of JG-98. AR protein disappeared within 6 hrs of 5-10 μ M JG-98 treatment. These high concentrations of JG-98 did not resensitize 22Rv1 CRPC cells to ADT based on Incucyte studies. Further, exposure of either 22Rv1 or C4-2 CRPC cells to these micromolar concentrations of JG-98 for 6 hrs resulted in depletion of both full-length AR and AR splice variant proteins, consistent with the data shown above. Together, these data suggest an alternative mechanism underlying the activity of JG-98 in CRPC that is independent of ADT resensitization.


To explore this possibility further, we used Incucyte analysis to determine the minimal concentration of JG-98 that is able to resensitize C4-2 CRPC cells to ADT, in this case enzalutamide. The data in Fig. 2, reveal that 25 – 50 nM JG-98 is sufficient for this purpose.

Fig.2. Incucyte growth plot of C4-2 CRPC cells in the presence of increasing amounts of JG-98 (left). Incucyte growth plot of C4-2 in the presence of either 25 or 50 nM JG-98 +/- 5 μ M ENZ (right).



Importantly, and in contrast to the earlier data reported by Moses et al (DOI: 10.1158/0008-5472.CAN-17-3728), after 1 - 4 days of treatment of 22Rv1 CRPC cells with 150 nM JG-98, full-length AR and AR splice variant expression was not changed (see Fig. 3).

Fig. 3. Western blot analysis of AR-FL and Arv7 in 22Rv1 treated with 150 nM JG-98 or JG-258 (negative control) for 1-4 days (JG-98) or 4 days (JG-258).



Taken together with all the previous data, we hypothesize that 25 - 150 nM JG-98, a concentration that is maximally effective in inhibiting mitochondrial proteostasis (Echtenkamp et al. PNAS Nexus, 2023, doi: 10.1093/pnasnexus/pgad115), is sufficient for resensitization of CRPC cells to ADT.

We generated orthogonal support for this hypothesis by examining the ability of the mitochondrial electron transport chain complex I inhibitor IACS-010759 to mimic the ability of low dose JG-98 to resensitize CRPC cells to ADT (see Fig. 4 below).





Fig. 4. Incucyte growth analysis over time while treating 22Rv1 cells with increasing concentrations of the mitochondrial complex I inhibitor IACS-010759 (top). Incucyte growth analysis of 22Rv1 cells grown in the presence of 10 nM or 20 nM IACS-010759 +/- 10 μ M ENZ (bottom). Although IACS is mechanistically distinct from JG-98, it is able to sensitize CRPC cells to ADT at very low nanomolar concentrations.



In the coming cycle, we will determine whether other insults to efficient mitochondrial OxPhos have a similar impact on resensitization of CRPC to ADT. We will also explore a requirement for AR expression. Finally, we will carry out in vivo studies to expand on our evaluation of 22Rv1 xenograft models (see below).

Specific Aim 3: The goal of Specific Aim 3 is to determine whether combinatorial activity can be demonstrated between Hsp40/Hsp70 inhibitors and specifically targeted metabolic inhibitors, such as the complex I inhibitor described above. The ability of certain metabolic inhibitors to synergize with or restore sensitivity to enzalutamide and/or abiraterone is a sub-task of SA3 and this possibility will be explored further in the next cycle. It should also be noted that complex I oxidizes NADH supplied by glycolysis and the TCA cycle to help establish a proton gradient across the inner mitochondrial membrane while generating electrons which pass along the electron transport chain, resulting in oxidative phosphorylation and ATP synthesis. While we found that complex I inhibition is able to resensitize these cells to ADT, in the next cycle we will determine whether this involves NADH oxidation and whether resensitization to ADT in CRPC cells can be antagonized by restoring the NADH/NAD ratio (redox balance) in CRPC without affecting OxPhos. Further, in the next cycle we will continue to explore the utility of non-invasive hyperpolarized magnetic resonance imaging (HP-MRSI) using novel probes that will give us a broader view of CRPC metabolic pathways, including glutamine and glucose directed probes.

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Emiliano Soto-Romero joined the project as a new Post-Bac Fellow in the Neckers lab who expects to stay for two years. He is being mentored by Frank Echtenkamp, a Staff Scientist in the Neckers lab, to develop research skills related to the studies described in the SOW, Specific Aims 2 and 3. He is also now prepared to evaluate the activity of the 11 C86 derivatives specifically targeted to the mitochondria which we now have in hand. Emilio is also able to take relevant courses at the FAES Graduate School, which are offered to him at no cost. He is encouraged to attend seminars, workshops and conferences related to his work. Genesis Rivera-Marquez continues as a Geneva Foundation employee and works on this project as a collaborator. She is able to attend virtual seminars, journal clubs, workshops and conferences and to take relevant courses at the FAES graduate school at no cost to her. Both Genesis and Emiliano will be co-authors on a manuscript currently in preparation.

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Publication and presentation at relevant scientific meetings.

What do you plan to do during the next reporting period to accomplish the goals?

We will submit at least one, and perhaps two, manuscripts for publication that describe our findings and delve deeper into the role of mitochondrial proteostasis in protein quality control in mitochondria and requirement for mitoribosome assembly/stability. We will pursue the hypothesis that this represents a novel vulnerability of CRPC. We will also devote a greater effort to focusing on Hsp40 inhibition as discussed in SA1, particularly whether targeting a C86 derivative to the mitochondria improves its efficacy in CRPC independent of its role in stabilizing androgen receptor.

4. IMPACT: Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

We identified a unique metabolic vulnerability of CRPC cells to inhibitors of the ETC and we showed synergy with the Hsp70 inhibitor JG-98. We also uncovered an impact of JG-98 on Hsp70-mediated transport of nuclear encoded mitochondrial subunit and assembly proteins from cytosol into mitochondria. This is likely to have a major impact on mitochondrial function as mitochondrial protein translation is inhibited, leading to incomplete assembly of ETC complexes. This in turn is accompanied by re-sensitization to ADT treatment.

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to Report

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to Report

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report

5. CHANGES/PROBLEMS: *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*

Nothing to Report

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

Nothing to Report

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

Nothing to Report

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to Report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

Nothing to Report

Significant changes in use or care of vertebrate animals

Nothing to Report

Significant changes in use of biohazards and/or select agents

Nothing to Report

6. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”*

- **Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Arielle Shkedi, Michael Adkisson, Andrew Schroeder, Walter L Eckalbar, Szu-Yu Kuo, Leonard Neckers, and Jason E. Gestwicki. Inhibitor Combinations Reveal Wiring of the Proteostasis Network in Prostate Cancer Cells. *J. Med. Chem.* 2021, 64, 14809–14821. (publication status: published; federal support acknowledged)

Arielle Shkedi, Isabelle R. Taylor, Frank Echtenkamp, Poornima Ramkumar, Mohamed Alshalalfa, Genesis M. Rivera-Marquez, Michael A. Moses, Hao Shao, Robert Jeffrey Karnes, Len Neckers, Felix Feng, Martin Kampmann, and Jason E. Gestwicki. Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. *Cell Chemical Biology.* 2022, 29, 490–501.

(publication status: published; federal support acknowledged)

Frank J. Echtenkamp, Ryo Ishida, Genesis M. Rivera-Marquez, Marisa Maisiak, Oleta T. Johnson, Jonathan H. Shrimp, Steve Ralph, Ian Nisbet, Matthew D. Hall, Jason E. Gestwicki, Leonard M. Neckers. Mitoribosome Sensitivity to Hsp70 Inhibition Uncovers Metabolic Liabilities of CRPC and Re-sensitizes to Androgen Deprivation Therapies. *PNAS Nexus*, 2023; 2:pgad115. doi: 10.1093/pnasnexus/pgad115.

(publication status: published; federal support acknowledged)

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to Report

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Presentation at Cell Stress Society International Virtual Meeting, September 2022: Targeting mitochondrial Hsp70 and the ETC: A unique vulnerability in prostate cancer.

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report

- **Other Products**

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- *data or databases;*
- *physical collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Jason Gestwicki: No Change

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to Report

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country) Partner’s contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner’s facilities for project activities);*
- *Collaboration (e.g., partner’s staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and*
- *Other.*

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ebrap.org/eBRAP/public/index.htm> for each unique award.*

AWARD CHART: Attached

9. APPENDICES: *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*